CSL Opens Waltham Vaccine Research, Development Facility

WALTHAM, MA — Waltham officials were on hand at a Monday ribbon cutting ceremony to mark the opening of a major biotechnology company's new central hub.

CSL hosted the ceremony to mark the official opening of its 225 Wyman St. facility. Custom-built, the new space is approximately 140,000 sq. ft., with 54,000 sq. ft. of lab space. The facility includes the first biosafety level 3 laboratory in Waltham.

The site will serve as CSL's central hub for current and future vaccine design, according to a company news release.

Coming off multiple years impacted by the COVID-19 pandemic, the company sees this new site as a place to study and develop vaccines for years to come.

"CSL's growing R&D presence in Waltham is the latest example of our investment in our future – which includes advancing our growing capabilities in disruptive technologies like next-generation mRNA," said Jon Edelman, Senior Vice President of the CSL Vaccines Innovation Unit.

"At this site, we aim to develop the vaccines that will help protect the public in the decades ahead and facilitate collaboration with local partners to drive our next wave of innovation."

Part of that collaboration, according to officials, is aided by the proximity to the region's colleges and universities.

"The Waltham site's location and our investment in this world-class facility will provide our talented people with the ideal environment to deliver the breakthroughs that CSL aims to achieve," said Ethan Settembre, Ph.D., Vice President, Research, CSL Vaccines Innovation Unit and site head for this facility.

"We are also excited that this location provides an opportunity for our scientists to collaborate closely with industry and academic partners, allowing greater access to ongoing innovation and talent."

CSL's global research and development organization has more than 2,000 employees in ten countries around the world, according to officials.

In addition to Waltham, the company has a research and development presence in King of Prussia, Penn.; Pasadena, Calif.; Melbourne, Australia; Bern, Switzerland; Amsterdam, Netherlands; and Marburg, Germany.